Allergan Acular PF
Executive Summary
"Fast relief" claim in promotional materials submitted by Allergan are without context, so company must discontinue use of brochure and any other materials that make claim, FDA says in July 23 letter. The brochure urges physicians to "prescribe Acular PF for fast relief from ocular pain and photophobia following incisional refractive surgery," FDA says. The letter was sent to Roche, which acquired the Acular (ketorolac ophthalmic solution) NDA when it bought Syntex. Allergan markets the product